Provectus Biopharmaceuticals Announces Investor Webinar for Fourth Quarter 2024 Conference Call
24 oct. 2024 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, Tenn., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that its Fourth Quarter 2024 Investor Update will...
Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference Call
10 oct. 2024 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, Tenn., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that it will host a conference call on Thursday,...
Provectus Biopharmaceuticals Announces Investor Webinar for 2024 Annual Meeting of Stockholders
13 juin 2024 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, Tenn., June 13, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that its 2024 annual stockholder meeting (the...
Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting
21 mai 2024 08h00 HE
|
Provectus Biopharmaceuticals Inc.
Accelerates wound closure and improves wound healing KNOXVILLE, TN, May 21, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today...
Provectus Biopharmaceuticals Announces Eight Presentations of Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2024 Annual Meeting
14 mai 2024 08h00 HE
|
Provectus Biopharmaceuticals Inc.
PDAT clinical outcomes for infectious keratitis from Brazil and Mexico KNOXVILLE, TN, May 14, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB:...
Provectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia)
02 mai 2024 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, May 02, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that the United States Patent and Trademark Office has...
Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation
16 avr. 2024 08h00 HE
|
Provectus Biopharmaceuticals Inc.
Names Ed Pershing as Chief Executive Officer and Dominic Rodrigues as President KNOXVILLE, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the...
Provectus Biopharmaceuticals Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting
11 avr. 2024 08h00 HE
|
Provectus Biopharmaceuticals Inc.
PV-10 demonstrated significant anti-tumor activity in vivo in head and neck cancers KNOXVILLE, TN, April 11, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the...
Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium
27 mars 2024 08h00 HE
|
Provectus Biopharmaceuticals Inc.
New Provectus Spinout Company Would Commercialize Combination Therapy of University’s Light Source Medical Device and Provectus’s Pharmaceutical-Grade Rose Bengal Sodium KNOXVILLE, TN, March 27,...
Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines
12 mars 2024 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, March 12, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that the United States Patent and Trademark Office...